Business Wire

4D Molecular Therapeutics and Roche Sign Collaboration Agreement for Gene Therapy Vector Discovery and Product Development

SAN FRANCISCO--(BUSINESS WIRE)--4D Molecular Therapeutics (4DMT), a leader in next-generation gene therapy vector discovery and product development, today announced a collaboration and license ...
Nasdaq

4D Molecular Therapeutics Announces Collaboration on Leading Machine Learning Technology and Expertise from U.C. Berkeley to Expand Therapeutic Vector Evolution Platform

EMERYVILLE, Calif., May 04, 2021 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene ...
Seeking Alpha

4D Molecular Therapeutics: R100 Vector Pushes Forward To Bring Q4 Of 2024 DME Data

The last time I wrote about 4D Molecular Therapeutics, Inc. (FDMT), it was in a Seeking Alpha article entitled “4d Molecular Therapeutics: Several Value Inflection Points To Watch In 2024.” In this ...
Healio

Astellas, 4D Molecular Therapeutics enter license agreement for retinotopic vector

Please provide your email address to receive an email when new articles are posted on . Astellas has gained the rights to utilize 4DMT’s R100 vector to deliver its unique genetic payloads. Astellas is ...
Business Wire

4D Molecular Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of 4D-125 by Intravitreal Injection for the Treatment of X-Linked Retinitis Pigmentosa

EMERYVILLE, Calif.--(BUSINESS WIRE)--4D Molecular Therapeutics (4DMT), a clinical-stage leader in the development of precision-guided AAV gene medicines based on directed evolution, announced that the ...
Business Insider

Analyst Expectations For 4D Molecular Therapeutics's Future

6 analysts have expressed a variety of opinions on 4D Molecular Therapeutics (NASDAQ:FDMT) over the past quarter, offering a diverse set of opinions from bullish to bearish. The table below provides a ...
Nasdaq

What 5 Analyst Ratings Have To Say About 4D Molecular Therapeutics

5 analysts have expressed a variety of opinions on 4D Molecular Therapeutics (NASDAQ:FDMT) over the past quarter, offering a diverse set of opinions from bullish to bearish. The table below provides a ...
Seeking Alpha

Astellas and 4D Molecular Therapeutics (4DMT) Enter into License Agreement to Use 4DMT's Proprietary Intravitreal R100 Vector for Rare Ophthalmic Targets

TOKYO and EMERYVILLE, Calif., July 10, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503) (President and CEO: Naoki Okamura, "Astellas") and 4D Molecular Therapeutics, Inc. (FDMT) (CEO: David Kirn, ...
Investing

Jefferies ups 4D Molecular Therapeutics shares target on viral vector potential and pipeline promise

On Monday, 4D Molecular Therapeutics (NASDAQ:FDMT) shares saw its price target significantly raised by investment firm Jefferies, from $30.00 to $58.00, while the firm maintained its Buy rating. The ...
Benzinga.com

Beyond The Numbers: 4 Analysts Discuss 4D Molecular Therapeutics Stock

4 analysts have shared their evaluations of 4D Molecular Therapeutics (NASDAQ:FDMT) during the recent three months, expressing a mix of bullish and bearish perspectives. The table below offers a ...
Pharmabiz

Astellas, 4D Molecular ink license agreement to use 4DMT’s proprietary intravitreal R100 vector for rare ophthalmic targets

Astellas Pharma Inc. and 4D Molecular Therapeutics, Inc. announced a license agreement under which Astellas gains rights to utilize the intravitreal retinotropic R100 vector invented by 4DMT for one ...